Posts in tag

new listings


MSD today announced that its new antibiotic has been registered by the Therapeutic Goods Administration for the treatment of common and problematic gram-negative pathogens.

A new atypical antipsychotic medication that provides a sustained improvement of the symptoms of schizophrenia with negligible effect on patients’ metabolic parameters has been welcomed by Australian experts.

Health Minister Sussan Ley says patients with rare chronic myeloid leukaemia and acute lymphoblastic leukaemia now have affordable access to a life-changing medicine that would normally cost up to $66,500 …

Health Minister Sussan Ley has criticised pharmaceutical companies for dragging their feet on bringing new drugs to the Australian market and prioritising applying to lucrative markets overseas. “Australia has a …

A new oral treatment alternative for patients with moderate to severe rheumatoid arthritis, will be available on the PBS from 1 October, 2015.

Nearly 3000 Australians with hepatitis C have progressed to severe liver disease in the last year, as thousands continue to wait for affordable access to curative medicines recommended for a …

Complementary Medicines Australia has welcomed the TGA’s announcement of approval of 10 new ingredients that have been assessed as suitable for use in listed medicines. “We welcome this streamlining of …

From yesterday, patients with melanoma have access to breakthrough medicine Keytruda on the PBS, Health Minister Sussan Ley has announced. The Government will invest $57 million to list the breakthrough …

The first in a new class of biologic medicine that acts to interrupt the inflammatory cycle and help clear the skin of patients with moderate-to-severe psoriasis has been added to the PBS from September 1, 2015.

The Generic and Biosimilar Medicines Association has welcomed the approval of biosimilar infliximab, Inflectra. Inflectra is the first biosimilar infliximab to be approved in Australia, providing an alternative, affordable treatment …

A government subsidy for a biologic to treat vision impairment caused by macular oedema in patients with diabetes or retinal vein occlusion (branch or central) will be available from 1 July.

MSD has welcomed the Federal Government’s announcement that patients with the most deadly form of skin cancer – advanced melanoma – will be able to access the company’s anti-PD1 immunotherapy …